Pappagallo M

MGGM Therapeutics, Kerhonkson, New York, USA.

2 papers

ArticlePsilocybin

Pharmacokinetics and safety of a modified-release psilocybin formulation: A SAD Phase I trial in normal-weight and overweight/obese participants.

Signor A, Comai S, Pasut G +9

Europe PMC2026
ArticlePsilocybin

Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms.

Colognesi M, Gabbia D, Signor A +30

Europe PMC2026